Kanghong Biotech

Kanghong is a China-based publicly traded pharmaceutical and biotechnology group focused on the discovery, development, manufacturing, and commercialization of medicines in ophthalmology, neuropsychiatry, gastroenterology, and related therapeutic areas. The company is best known for Lumitin (conbercept ophthalmic solution), a marketed anti-VEGF biologic for retinal vascular diseases, and it also maintains a broader portfolio of chemical drugs, biologics, and traditional Chinese medicines. Its innovation pipeline includes ophthalmic gene therapy, ophthalmic biologics, CNS programs, and oncology candidates, with active clinical development programs such as KH631, KH906, KH110, KH801, and KH815. Kanghong operates in-house R&D and GMP manufacturing and has subsidiaries across China, the United States, and Singapore. The requested name "Kanghong Biotech" most closely maps to the active Kanghong group and its biotech subsidiary, Chengdu Kanghong Biotechnology.